The interplay between cell death pathways and the ncRNA regulatory networks profoundly influences chemoresistance in GC, andiphering these mechanisms offers a theoretical basis for developing biomarkers and combination strategies that overcome resistance, ultimately improving patient outcomes.
This is the first comprehensive study that redefines chemoresistance as a proliferative, MYC-driven state and uncover SRM as a tractable vulnerability, offering new avenues for therapeutic intervention across diverse epithelial malignancies.
Mohammed M. A. Inayatullah, Engin Demirdizen, Z. Keepers et al.· Genome Medicine· 0 citations
Targeting ncRNAs via various therapeutic approaches, including herbal compounds and synthetic peptides, has shown hopeful findings in reversing taxane resistance in breast cancer, highlighting a promising avenue for the management of taxane resistance in breast cancer.
Overall, siRNA-based strategies may play a crucial role in the future development of precision-oriented therapeutic frameworks in GC research, and this review emphasizes the integration of molecular target selection with delivery system design in a GC-specific context.
Gheysar Seifollahnezhad, B. Erdağ· Experimental oncology· 0 citations
Drug resistance continues to pose a significant challenge, accounting for a large proportion of relapses and playing a major role in cervical cancer-related mortality worldwide. Emerging evidence has indicated that the aberrant expression of non-coding RNAs, especially circular RNAs (circRNAs), long non-coding RNAs (ln...
Lilian Makgoo, Z. Mbita· Frontiers in Oncology· 0 citations
A framework for a deeper understanding of the complex biological basis of PTX resistance is provided and insights are offered into the development of more precise therapeutic strategies for overcoming resistance.
Ming-Jun Zhu, Bing-Wen Zhou, Lu Wang et al.· Frontiers in Pharmacology· 0 citations
The effectiveness of chemotherapy in colorectal cancer (CRC) is significantly reduced by acquired chemoresistance to 5-fluorouracil (5-FU), oxaliplatin and irinotecan. This structured narrative review synthesises mechanistic, preclinical, translational and clinical evidence underlying resistance to these agents. Distin...
D. Bartusik-Aebisher, Izabella Wilk, B. George et al.· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
